Wipfli Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Wipfli Financial Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$13K	Buy	+405	New	+$14.9K	﹤0.01%	1733

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Wipfli Financial Advisors's ARKG Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in ARK Genomic Revolution ETF (ARKG) in Q3 2022: 405 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1733 among its holdings.

311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

Wipfli Financial Advisors held 405 shares of ARK Genomic Revolution ETF worth $13K as of Q3 2022.
ARK Genomic Revolution ETF was a new Wipfli Financial Advisors position in Q3 2022.
ARK Genomic Revolution ETF made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1733 holding.
311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.